Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter study

Skin Cancer

Real-world efficacy and safety of axitinib in combination with anti-programmed cell death-1 antibody for advanced mucosal melanoma

Eur J Cancer

Tang B, Mo J, Yan X, Duan R, Chi Z, Cui C, Si L, Kong Y, Mao L, Li S, Zhou L, Lian B, Wang X, Bai X, Xu H, Li C, Dai J, Guo J, Sheng X

doi: 10.1016/j.ejca.2021.07.018

Skin Cancer

Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study

Lancet Oncol

Pires da Silva I, Ahmed T, Reijers ILM, Weppler AM, Betof Warner A, Patrinely JR, Serra-Bellver P, Allayous C, Mangana J, Nguyen K, Zimmer L, Trojaniello C, Stout D, Lyle M, Klein O, Gerard CL, Michielin O, Haydon A, Ascierto PA, Carlino MS, Lebbe C, Lorigan P, Johnson DB, Sandhu S, Lo SN, Blank CU, Menzies AM, Long GV

doi: 10.1016/S1470-2045(21)00097-8

SPECIAL REPORT

Multiple Myeloma (MM)

Traitement du myélome multiple récidivant/réfractaire

SPECIAL REPORT

Multiple Myeloma (MM)

Therapie des rezidivierten/refraktären Multiplen Myeloms

Breast Cancer

Recent Developments in Metastatic Breast Cancer

healthbook TIMES Oncology Hematology

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Clinical impact of probiotics on the efficacy of anti-PD-1 monotherapy in patients with non-small cell lung cancer: A multicenter retrospective survival analysis study with inverse probability of treatment weighting

★ 1 Recommended by Dr Wolf-Dieter Janthur, Faculty Member

Int J Cancer

Takada K, Shimokawa M, Takamori S, Shimamatsu S, Hirai F, Tagawa T, Okamoto T, Hamatake M, Tsuchiya-Kawano Y, Otsubo K, Inoue K, Yoneshima Y, Tanaka K, Okamoto I, Nakanishi Y, Mori M

doi: 10.1002/ijc.33557

Skin Cancer

Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma

Eur J Cancer.

Zimmer L, Apuri S, Eroglu Z, Kottschade LA, Forschner A, Gutzmer R, Schlaak M, Heinzerling L, Krackhardt AM, Loquai C, Markovic SN, Joseph RW, Markey K, Utikal JS, Weishaupt C, Goldinger SM, Sondak VK, Zager JS, Schadendorf D, Khushalani NI

doi: 10.1016/j.ejca.2017.01.009.

Skin Cancer

Randomized Phase II Study of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma

J Clin Oncol

Yan X, Sheng X, Chi Z, Si L, Cui C, Kong Y, Tang B, Mao L, Wang X, Lian B, Li S, Bai X, Zhou L, Dai J, Yao H, Guo J

doi: 10.1200/JCO.20.00902

SPECIAL REPORT

Skin Cancer

Related content

Real-world efficacy and safety of axitinib in combination with anti-programmed cell death-1 antibody for advanced mucosal melanoma

Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study

Traitement du myélome multiple récidivant/réfractaire

Therapie des rezidivierten/refraktären Multiplen Myeloms

Recent Developments in Metastatic Breast Cancer

Clinical impact of probiotics on the efficacy of anti-PD-1 monotherapy in patients with non-small cell lung cancer: A multicenter retrospective survival analysis study with inverse probability of treatment weighting

Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma

Randomized Phase II Study of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma

Bavencio® (Avelumab): Treatment for Metastatic Merkel Cell Carcinoma1,2

Bavencio^® (Avelumab): Treatment for Metastatic Merkel Cell Carcinoma^1,2